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At a Glance Commentary (200/200)
Scientific knowledge on the subject:
Multiple inhaled antibiotic trials in bronchiectasis have not met their primary 
endpoints. To date the reason for heterogeneous responses to inhaled antibiotics have 
not been identified. Airway bacterial load is a key component of bronchiectasis 
pathogenesis and has been previously associated with increased airway inflammation 
and poor clinical outcomes, especially in those patients with high bacterial load. We 
hypothesized that higher bacterial load would be a stable trait associated with worse 
airway inflammation and worse quality of life, and therefore patients with the highest 
bacterial load would benefit most from inhaled antibiotic treatment. 
What this study added to the field:
This is the first study to identify an inhaled antibiotic response phenotype based on 
baseline bacterial load. Patients with high bacterial load had higher airway 
inflammation and worse quality of life but responded with a mean in quality of life that 
exceeds the minimum clinically important difference with aztreonam treatment. The 
percentage of patients with a clinically meaningful improvement was higher with 
aztreonam compared with placebo at the end of both treatment cycles only in patients 
with baseline high bacterial load. The potential for bacterial load to guide antibiotic 
therapy for patients with bronchiectasis should be prospectively tested.  
ABSTRACT  (248/250)
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Rationale: The principal underlying inhaled antibiotic treatment in 
bronchiectasis is that airway bacterial load drives inflammation, and therefore 
antibiotic treatment will reduce symptoms. 
Objective: We performed 3 studies to 1) determine the relationship between 
bacterial load and clinical outcomes, 2) assess the stability of bacterial load over time 
and 3) test the hypothesis that response to inhaled antibiotics would be predicted by 
baseline bacterial load.
Methods: Study 1+2: Prospective studies including adults with bronchiectasis. 
Study 3: Post-hoc analysis of a randomized trial of inhaled aztreonam. A priori patients 
were divided into low (<105 colony forming units (cfu)/g), moderate (105-106cfu/g) and 
high bacterial load (≥107cfu/g) using quantitative sputum culture.
Measurements and main results: Bacterial load was a stable trait associated 
with worse quality of life and more airway inflammation in studies 1, 2 and 3. In study 
3, patients with high bacterial load showed an improvement in the primary endpoint 
(Quality of Life Bronchiectasis Respiratory Symptoms Score at week 4) in favor of 
aztreonam (mean difference of 9.7 points (95% confidence interval 3.4-16.0), p=0.003). 
The proportion of patients who achieved an increase above the Minimum Clinically 
Important Difference was higher in the aztreonam group at week 4 (63% vs 
37%,p=0.01) and at week 12 (62% vs 38%,p=0.01) only in high bacterial load patients.
Conclusions: Improvement of quality of life with inhaled aztreonam was only 
evident in patients with high bacterial load. Bacterial load may be a useful biomarker 
of severity of disease and treatment response. 
Word count of the abstract: 248
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Word count of the manuscript: 2839
Key-words: Quality of life, QoL-B, airway inflammation, inhaled Aztreonam. 
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INTRODUCTION
Bronchiectasis is a common chronic respiratory disease characterized by 
bronchial dilatation leading to daily productive cough and recurrent respiratory 
infections (1). A renewed interest in the disease has been seen in recent years, 
resulting in more clinical research with the aim of developing new treatments (2). 
Several clinical trials have attempted to adapt inhaled antibiotic treatments which are 
licensed for cystic fibrosis. The principle underpinning inhaled antibiotic treatment in 
bronchiectasis is that decreases in bacterial load will in turn reduce symptoms and  the 
frequency of exacerbations (3, 4). However, most trials have not reached their primary 
endpoints in bronchiectasis. Two large phase 3 randomized trials of inhaled aztreonam 
concluded no improvement in quality of life (5). Multiple other trials involving 
nebulized colistin (6), dry powder ciprofloxacin (7, 8) and nebulized liposomal 
ciprofloxacin (9) have also not consistently reach primary endpoints. The new 
European Respiratory Society (ERS) guidelines found no strong clinical evidence in 
support of inhaled antibiotic therapy as a treatment (10). Despite extensive subgroup 
analyses, the reasons for inconsistency between bronchiectasis inhaled antibiotics 
trials have not been explained.
Airway bacterial load is a key component of bronchiectasis pathogenesis (11). 
Patients are chronically infected with a variety of bacterial pathogens, resulting in a 
vicious cycle of infection and inflammation with persistent respiratory symptoms and 
further airway damage (12). Previous studies have demonstrated a direct relationship 
between airway bacterial load and both airway and systemic inflammation (13, 14). 
Multiple studies across several diseases have suggested an “inflammatory threshold” 
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above 107 colony forming units (cfu)/gram where patient have more inflammation, 
worse symptoms and more exacerbations (15–17). Both systemic and inhaled 
antibiotic treatment reduces bacterial load, with greatest benefits in terms of reduced 
airway and systemic inflammation in the patients with the highest bacterial load (15). 
However, no recent clinical trials focused on inhaled antibiotics have considered 
whether inhaled antibiotic response is predicted by baseline bacterial load (5–8). 
Therefore, we hypothesized that higher bacterial load would be associated with 
worse airway inflammation and quality of life and therefore patients with the highest 
bacterial load would benefit most from inhaled antibiotic treatment.
METHODS 
Study design
This research is composed of three components. Study 1 examines the 
relationship between bacterial load and quality of life and airway inflammation in 
patients with bronchiectasis. Study 2 evaluates the stability of bacterial load in two 
prospective cohorts: one in patients receiving systemic antibiotic treatment for 
exacerbations, and a second cohort evaluating day to day variability in clinically stable 
patients. Study 3 describes a post-hoc analysis of patients enrolled in two randomized 
double blind trial of inhaled aztreonam to test the hypothesis that response would be 
predicted by bacterial load in bronchiectasis. All studies described here were approved 
by the relevant research ethics committees (approval numbers 11/AL/0286, 
12/ES/0059, 16/ES/0047). 
Study 1 
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This was a prospective study of 189 bronchiectasis patients. Inclusion and 
exclusion criteria, recorded data and inflammatory markers evaluated are described in 
on-line supplement.  
Sputum was processed for qualitative and quantitative bacteriology as 
previously described (15, 18). A priori patients were divided into low bacterial load 
(<105 cfu/g), moderate bacterial load (105-106 cfu/g) and high bacterial load (≥107 
cfu/g).
Study 2
Two prospective studies were performed to demonstrate the repeatability of a 
high bacterial load phenotype in bronchiectasis. We hypothesized that groups of 
patients with different baseline levels of bacterial load would maintain similar bacterial 
load levels throughout follow-up, including after recovery from antibiotic treatment. 
First, 26 patients with bronchiectasis were followed-up for one year, and sputum 
analyses were performed at baseline, after receiving systemic antibiotic treatment due 
to an acute exacerbation (19) and after at least three months of recovery. In a second 
study of 10 stable patients with bronchiectasis (5 with idiopathic/post-infective and 5 
with CF bronchiectasis) patients were followed-up for 14 days, and sputum analyses 
were performed at days 1,3,5,7 and 14. Further details are provided in the on-line 
supplement.
Study 3
We conducted a secondary analysis of two randomized double-blind, placebo-
controlled phase 3 trials of Aztreonam for inhalation solution (AZLI) in bronchiectasis 
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(AIR-BX1 and AIR-BX2) (5). The original informed consent form for this study contained 
an optional consent for future exploratory analysis of participants data. Only data from 
patients that had given written consent for future re-use of their data were included in 
this analysis. A summary of these trials is provided in the on-line supplement. Patients 
received two 4-week cycles of double-blind inhaled treatment with AZLI 75 mg or 
placebo given three times a day, separated by 4 weeks off-treatment. 
The primary endpoint was change in the QoL-B-RSS between baseline and week 
4. Minimum Clinical Important Difference (MCID) was considered an increase of 8 
points (20). Secondary outcomes were changes in the QoL-B-RSS at week 12, 6 minute 
walk distance at week 4, EQ-5D questionnaire at week 4 and frequency of 
exacerbations during the study. Bacterial load data throughout the study was used to 
further demonstrate the repeatability of bacterial load over time.
Bacterial load in cfu /g of target Gram-negative pathogens was measured in 
sputum at baseline by a central laboratory. Based on our own previous work (15, 17), 
we divided patients a priori into 3 groups based on their quantitative bacterial culture;  
low bacterial load (<105 cfu/g), moderate bacterial load (105-106 cfu/g) and high 
bacterial load (≥107 cfu/g).
Statistical analyses 
Statistical analysis was performed using the SPSS 22.0 software. Categorical 
variables are presented by frequencies and percentages, and differences were 
analysed using the χ2  test or Fisher exact test when required. Continuous variables are 
presented as mean and standard deviation (SD), or median and interquartile range 
(IQR) when data was not distributed normally. Differences in continuous variables 
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were analysed using Student t and ANOVA tests, or their corresponding non-
parametrical tests when required. Pearson correlation was used to examine the 
relationship between linear variables. We defined statistical significance as a two-
tailed p<0.05.
RESULTS
Study 1
One hundred eighty-nine clinically stable patients were recruited for the study. 
Table 1 shows the demographic characteristics of the study population. Mean age ( 
SD) was 64 ( 12 years old), 56% were female and mean FEV1 was 72 ( 25) % of 
predicted. Most patients were classified as Idiopathic (46%) and post-infective (18%). 
P. aeruginosa was present in the sputum of 34 (18%) patients, and mean QoL-B-RSS at 
baseline was 56 (22) points. 
Mean bacterial load was 6.6 (1.7) log 10 cfu/g. Fifty-two patients (28%) had 
low bacterial load, 51 patients (26%) had moderated bacterial load and 86 patients 
(46%) had high bacterial load. Patients with high bacterial load were older, had lower 
FEV1, and high percentage of P. aeruginosa. No other differences among groups were 
found (Table 1).
Bacterial load was weakly associated with QoL-B-RSS (r=-0.20, p=0.004) and 
disease severity (r=0.38, p<0.001 with BSI score and r=0.34, p<0.001 with FACED 
score). Compared to those with moderate and low bacterial load, patients with high 
bacterial load had worse QoL-B-RSS (50 (21) vs 59 (24) vs 61 (22) points, p=0.01) 
and more severe disease (9.3 (4.2) vs 7.7 (4.6) vs 5.2 (3.1), p<0.001 points in BSI 
score). (Figure 1).
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 Patients with high bacterial load had higher sputum neutrophil count (median 
(IQR) of 9.2 (5.2-15.7) vs 5.2 (2.5-9.2) vs 3.3 (1.8-6.6) 106cells/g, p=0.007) and higher 
sputum myeloperoxidase activity (1.89 (0.58-6.34) vs 0.97 (0.06-2.21) vs 0.12 (0.01-
1.02) U/mL , p<0.001) (Figure 1).  In addition, higher CXCL8 (38.3 (27.5-53.0) vs 34.1 
(18.2-44.7) vs 33.7 (21.1-44.2) ng/mL) and TNF- (1010.5 (418.8-2941.8) vs 520.0 
(77.8-1400.6) vs 829.2 (177.8-3414.2) ng/mL) concentrations were observed in the 
patients with high bacterial loads, though the differences between the groups were 
not statistically significant (p=0.08, 0.2).
Study 2
Twenty-six patients with bronchiectasis were included in the exacerbation 
study. Patient characteristics are shown in table E1 in the online supplement. Fourteen 
patients (54%) had high bacterial load at baseline, while 7 patients (27%) had 
moderate and 5 (19%) had low bacterial load. 
Mean bacterial load decreased in all groups after antibiotic treatment 
(p<0.001). However, during the follow up, it increased again in all groups (p<0.001) 
(Figure 2A). Eleven out of 14 patients with high bacterial load at baseline (78%) also 
had high bacterial load during follow up. 
Ten clinically stable patients were included in the stability study. Demographic 
characteristics of the patients are described in the table E2 in the online supplement. 
Eight out of the 10 patients (80%) maintained similar levels of bacterial load during the 
follow-up, while only n=2 patients (20%) experienced significant changes (figure 2B). 
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No differences between patients with CF and idiopathic/post-infective bronchiectasis 
were found.
Study 3
440 patients out of 540 (81%) had consented to have their data reanalyzed 
(n=181 from the AIR-BX 1 and n=259 from AIR-BX2). There were no significant 
demographic differences between those consenting to reanalysis and the full cohort of 
all subjects in the original trials (table E3 in the on-line supplement).
 Table 2 shows the main clinical characteristics patients included in the study. 
Mean age (SD) was 64 ( 13) years old, 69% were female and mean FEV1 was 62 
(20) % of predicted. P. aeruginosa was present in the sputum of 357 patients (80%), 
and mean QoL-B-RSS at baseline was 56 (18) points. No differences among baseline 
characteristics of patients from AIR-BX1 and AIR-BX 2 were found. 
A total of 421 patients had documented baseline bacterial loads, with a mean 
of 5.1 (2.3) log10 cfu/g. Bacterial load was weakly, and negatively, associated with 
baseline FEV1 % predicted (r=-0.19, p=0.0003) and baseline QoL-B-RSS (r=-0.11, 
p=0.03). Baseline bacterial load was significantly higher in patients with P. aeruginosa 
(mean 5.6 (2.1) log10cfu/g vs 3.5 (1.8) log10cfu/g, p<0.001) when compared to 
those patients with other Gram-negative bacteria on sputum at baseline. 147 patients 
(35%) had low bacterial load, 172 patients (41%) had moderate bacterial load and 102 
patients (24%) had high bacterial load. No differences among clinical characteristics 
according to bacterial load were found, except that patients with high bacterial load 
had higher percentage of P. aeruginosa (see table E4 in the on-line supplement).
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369 patients with documented baseline bacterial load (88%) completed the 
double blind treatment period. 
The consistency of sputum bacterial load within the 3 groups over time demonstrated 
in study 2 was confirmed in the AIRBX studies. Figure 3A shows sputum bacterial load 
in patients treated with aztreonam demonstrating that the mean bacterial load 
remained consistent between the high, moderate and low groups in two pre-
treatment visits (screening- visit 1 and baseline- visit 2). Bacterial load was reduced 
with aztreonam treatment at day 14 on-treatment- visit 3, and day 28 on-treatment- 
visit 4. Following drug discontinuation bacterial load returned to a mean level 
equivalent to the group baseline. Similar behavior was observed over the second 
treatment cycle (figure 3A). In placebo patients clear differences between the three 
groups were observed at each time point indicating that bacterial loads remain stable 
in these groups (figure 3B). 
Primary endpoint
Comparing AZLI vs placebo, there was no improvement in QoL-B-RSS at week 4 with 
AZLI treatment for patients with low bacterial load (mean difference 1.6, 95% 
Confidence Interval -4.9 – 8.30, p= 0.6) and moderate bacterial load (mean difference 
0.9, 95CI -4.8 – 6.8, p= 0.8). However, there was a clear difference in favor of AZLI 
treatment above the MCID in patients with baseline high bacterial load (mean 
difference 9.7, 95CI 3.4 – 16.0, p=0.003) (Figure 4A). All mean differences refer to a 
comparison in the change in QOL-B between aztreonam and placebo treatment. An 
increase in QoL-B RSS of greater than or equal to 8 points is regarded as clinically 
meaningful. We therefore analysed the proportion of responders stratified by baseline 
bacterial load. There was no significant difference in the percentage of responders in 
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patients with low or moderate bacterial load. In patients with high bacterial load, 63% 
achieved a QOL-RSS increase above the MCID compared to 37% of patients in the 
placebo group (p=0.01) (Figure 4B). 
The response in patients with high bacterial load was consistent and unaffected 
by patients characteristics, with mean differences favoring AZLI treatment in all 
subgroups including FEV1 (50% or <50%), QoL-B-RSS (60 or <60 points), sex and 
patients with P. aeruginosa. 
In the original AIR-BX1 and AIR-BX2 studies (5), AIR-BX2 found a significant 
effect of AZLI on QoL-B-RSS (mean difference 4.6, 95CI 1.1 – 8.2, p=0.01), while AIR-
BX1 did not (mean difference 0.8, 95CI -3.1 – 4.7, p=0.6). We hypothesized this 
difference may have been due to lower numbers of patients with high bacterial load in 
AIR-BX1 vs AIR-BX2 and indeed as shown in Figure 5A, more than double the number 
of high bacterial load patients were seen in AIR-BX 2 (75/259 (29%) vs 27/181 (15%), 
p<0.001). When effects in high bacterial load subjects were compared between trials 
there was a consistent treatment response regardless of other baseline characteristics. 
(Figure 5B).
Analysis of the 12 week secondary endpoints supported the primary analyses 
with no benefit in patients with low and moderate bacterial load (mean difference of -
1.6 (95%CI -11.8 – 8.5, p=0.7) and 1.7 (95CI -4.7 – 8.1, p=0.6), respectively), but a mean 
difference of 5.5 (95CI -1.7 – 12.7, p=0.1) in those with high bacterial load. The 
percentage of patients with an improvement in QOL-B RSS above the MCID was 62% 
for aztreonam vs 38% for placebo at the 12 week visit (p=0.01) for patients with high 
bacterial load with no difference in responders for low and moderate groups.
Secondary endpoints
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For the secondary endpoints of reduction in CFU at week 4, aztreonam reduced 
bacterial load by 2 log units (95% CI 1.84-2.14,p<0.0001) compared to placebo in the 
high bacterial load group.  This effect was superior that seen in the moderate bacterial 
load group (mean difference 0.98 log units 95% CI 0.92-1.03,p<0.0001). The effect was 
lowest in the group with lower bacterial load, 0.47 log units 95% CI 0.29-
0.65,p<0.0001) (figure 3A/B). There were no overall improvements in the EQ5D or 6-
minute walk distance between the groups and no benefit of aztreonam treatment on 
exacerbation frequency in the original AIR-BX analysis.
Patients with higher bacterial load had the higher numerical improvement in 6-minute 
walk distance at week 4, 18m (95% CI -5 to 41.3, p=0.1), compared to a deterioration 
of -12m in the moderate group (95% CI -27.9 to 4.0, p=0.1). The low bacterial load 
group improved by 14m (95% CI -4 to 34,p=0.1).  There were 155 exacerbations during 
the study in 131 patients. Analysis of exacerbation frequency was limited by the small 
number of events in each subgroup, but no impact of aztreonam of exacerbations was 
observed in the high (IRR 1.02 95% CI 0.80-1.29,p=0.9), moderate (IRR 1.13 95% CI 
0.96-1.34,p=0.1) or low (IRR 0.92 95% CI 0.76-1.12,p=0.4) bacterial load group. No 
between group differences were observed in the EQ5D at any timepoint. 
DISCUSSION
In our study, we demonstrated that high airway bacterial load is associated 
with worse quality of life and increased airway inflammation in bronchiectasis. In 
addition, high bacterial load remained elevated over time during clinical stability and 
returned to high levels after suppression with antibiotic treatment. This led us to 
reanalyze two previously published negative randomized controlled trials (5) , where 
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for the first time we have demonstrated a consistent predictor of inhaled antibiotic 
response by showing that patients with elevated baseline bacterial loads had a clear 
improvement in respiratory symptoms when treated with aztreonam compared to 
placebo. These results were consistent both in terms of the mean improvement in 
quality of life, but also in the proportion of patients achieving a clinically meaningful 
response at 4 and also 12 weeks. These findings suggested that bacterial load is a key 
component in the heterogeneous response to inhaled antibiotic treatment in 
bronchiectasis. 
To the best of our knowledge, this is the first study to describe an inhaled 
antibiotic response phenotype. Most of the recent clinical trials on inhaled antibiotics 
in bronchiectasis have not reached their primary outcomes and identifying the 
response phenotype has been identified a key research priority (7, 8, 21). Haworth et 
al (6) allocated patients with chronic P. aeruginosa infection to either nebulized 
colistin or placebo, and the study did not meet its primary endpoint of time to first 
exacerbation. The international trials RESPIRE 1 (7) and RESPIRE 2 (8)  and ORBIT 3 and 
ORBIT 4 (9) have assessed different formulations of inhaled ciprofloxacin in patients 
with and without P.aeruginosa infection, and primary endpoints (time to first 
exacerbation, frequency of exacerbations) were reached in some trials (7, 9) but not 
met in replicate trials (8, 9). Clinical parameters such as lung function or microbiology 
were not sufficient in any of these trials to define response populations emphasizing 
the need for a biomarker such as bacterial load. In AIR-BX1 and AIR-BX2 (5), the 
primary outcome (changes in QoL-B-RSS) was reached in AIR-BX2 but not in AIR-BX1, 
even in AIR-BX2 the difference was below the MCID. We demonstrate that the 
difference between AIR-BX1 and AIR-BX2 studies may be explained by the much lower 
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bacterial load in AIR-BX1 and that responses were quite consistent when controlling 
for bacterial load. It would be important to now apply this knowledge to other 
inconsistent trial populations.
Airway bacterial load was shown to be important on clinical outcomes in 
bronchiectasis (13–15, 17). In our study, we demonstrated that high bacterial load is 
associated with severity of disease (both BSI and FACED scores), worse quality of life 
(QoL-B-RSS) and increased airway inflammation. The “threshold” of 107 cfu/gr to 
detect patients with high bacterial load was previously related to airway inflammation, 
neutrophil elastase activity and increased exacerbations in bronchiectasis (15, 17). In 
COPD, this cut-off has been related to airway inflammation (16), which has been 
associated with poor outcomes in several studies (22, 23). Therefore, patients with a 
bacterial load higher than this threshold could be the most suitable to receive 
treatments such as inhaled antibiotics.
Some clinical trials in bronchiectasis have evaluated baseline bacterial load. 
Interestingly, two small randomized controlled trials which included patients with the 
highest bacterial load showed positive results (18, 24). Patients who received inhaled 
tobramycin had a mean baseline bacterial load of 7.1 (1.4) log10 cfu/g, and 
experienced an improvement in their medical condition (24). In the most positive 
study published on inhaled antibiotics in bronchiectasis to date, patients who received 
nebulized gentamicin had a baseline bacterial load of 8.0 (7.6 – 8.2) log10 cfu/g, which 
is the highest baseline bacterial load included in all studies. After 12 months of 
treatment, these patients experienced an improvement in quality of life and a 
decrease in exacerbation frequency (18). On the other hand, patients included in AIR-
BX studies (5) presented the lowest baseline bacterial load (5.1 (2.3) log10cfu/g). 
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RESPIRE 1 and RESPIRE 2 did not evaluated baseline bacterial load (7, 8). Limiting study 
inclusion criteria to include only those patients with high bacterial load may enrich for 
those patients more likely to respond to therapy. As high bacterial load patients are a 
subgroup, it is possible this could make trials more difficult to recruit, but this decrease 
in eligible patients may be offset by a greater treatment effect and if bacterial load is 
the key treatable trait, it is possible that other inclusion and exclusion criteria could be 
relaxed.
The stability over time of high bacterial load suggests this microbiological 
characteristic meets the criteria to be considered as a phenotype, as it is measurable, 
consistent over time and linked to relevant outcomes (25). In our study, we 
demonstrated that most of the patients with high bacterial load did not experience 
changes in a day to day comparison and were recovered after receiving antibiotic 
treatment. Findings in our single centre UK studies were then confirmed in the AIR-BX 
studies where remarkable consistency in the 3 bacterial load groups was observed 
over the entire treatment period. The mean bacterial load remained consistent 
throughout the study in the placebo group, with only modest reductions at some 
timepoints likely due to antibiotic treatment of exacerbations. In the aztreonam group, 
consistent with data we obtained with exacerbation treatment, aztreonam produces a 
reduction in CFU/g during treatment but the mean level of bacterial load returned to 
the baseline level after discontinuation of treatment. These findings suggested that 
bacterial load is a consistent trait that will be associated with poor outcomes without 
treatment making it a key “treatable trait” according to recent concepts (2). The three 
studies included in our analysis are heterogeneous in terms of the patient population 
included, as studies 1 and 2 included a broad representative population of 
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bronchiectasis patients while study 2B included patients with idiopathic/post-infective 
bronchiectasis and CF. Finally, the AIR-BX studies included only patients with chronic 
Gram-negative airway infection. The heterogeneity of these populations may be 
viewed as a limitation but we regard it as a strength because we have identified 
consistent results across multiple different patient populations and a total sample size 
of 646 patients. This replication and validation of our findings suggests they are robust 
and likely to be reproduced in future studies. 
Our study has limitations.  First, we performed a post-hoc analysis and 
therefore results need to be confirmed in further prospective studies. Second, not all 
subjects included in AIR-BX1 and AIR-BX2 studies were available for reanalysis, 
although no differences were observed between available and unavailable patients. 
Third, the results of our study are based on airway bacterial load determined by 
culture. This bacterial load measurement is restricted to a set of pre-defined Gram-
negative pathogens. In the future, it is likely that molecular diagnostic tests will replace 
or at least supplement data obtained from culture. It must be emphasised that the 
results of our study may not be directly transferable to molecular assays which 
measures, for example, 16s rRNA load, since this would quantify all organisms 
including “pathogens” and “non-pathogens”. Targeted PCR directed against, for 
example, P. aeruginosa or a limited set of organisms is possible and widely performed 
in research studies. These also currently have limitations such as inability to 
differentiate between viable and non-viable bacteria. Therefore a future study is 
required to evaluate the relationship between culture based and molecular based 
assessments of bacterial infection and response to antibiotic therapy.”Fourth, the AIR-
BX studies were not long enough or sufficiently powered to look at exacerbations or 
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other efficacy endpoints such as 6-minute walk distance or EQ5D. Bacterial load is 
known to predict exacerbations (15), and future studies should determine if inhaled 
antibiotics also decrease exacerbations in high bacterial load patients.
In conclusion, we have shown that bacterial load is potentially a key 
bronchiectasis treatable trait that predicts response to inhaled antibiotics. 
Table 1. Patient demographics of all study population and divided according to 
bacterial load
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All
n=189
Low
bacteria load
n=52
Moderate
bacterial load
n=51
High
bacterial load
n=86
p value
Age, years
Mean (SD)
64.7 (11.8) 60.0 (14.3) 65.3 (11.3) 67.2 (9.6) 0.002
Female sex 107 (56.6) 30 (57.7) 29 (56.9) 48 (55.8) 0.9
FEV1 % predicted
Mean (SD)
71.8 (25.1) 75.03 (28.1) 77.5 (23.9) 66.6 (23.1) 0.02
BMI 
Mean (SD)
26.1 (5.5) 26.5 (5.08) 25.2 (6.3) 26.5 (5.3) 0.3
Pseudomonas aeruginosa* 34 (18) 3 (5.8) 6 (11.8) 25 (29.1) 0.001
Haemophilus Influenzae 77 (41) 18 (35) 17 (33) 42 (49) 0.1
Moraxella catarrhalis 35 (19) 5 (10) 8 (16) 22 (26) 0.053
Staphylococcus aureus 33 (17) 5 (10) 7 (14) 11 (13) 0.8
Streptococcus pneumoniae 14 (7) 8 (15) 2 (4) 4 (5) 0.035
Enterobacteriaceae 42 (22) 12 (23) 10 (20) 20 (23) 0.9
Smoking status
      Never 115 (60.8) 33 (63.5) 28 (54.9) 54 (62.8) 0.4
      Ex-smoker 67 (35.4) 19 (36.5) 20 (39.2) 28 (32.6)
      Current 7 (3.7) 0 3 (5.9) 4 (4.7)
Aetiology
      Idiopathic 87 (46) 23 (44.2) 20 (39.2) 44 (51.2) 0.3
      Postinfective 35 (18.5) 11 (21.2) 11 (21.6) 13 (15.1) 0.5
      Previous ABPA 25 (13.2) 4 (7.7) 5 (9.8) 16 (18.6) 0.1
      Asthma 7 (3.7) 2 (3.8) 3 (5.9) 2 (2.3) 0.5
      COPD 7 (3.7) 1 (1.9) 4 (7.8) 2 (2.3) 0.1
      Rheumatoid arthritis 5 (2.6) 1 (1.9) 1 (2.0) 3 (3.5) 0.8
      Immunodeficiency 8 (4.2) 5 (9.6) 2 (3.9) 1 (1.2) 0.05
      Sarcoidosis 2 (1.1) 2 (3.8) 0 0 0.07
      IBD 6 (3.2) 1 (1.9) 4 (7.8) 1 (1.2) 0.08
Data are presented as n(%) unless otherwise indicated.
FEV1=forced expiratory volume in 1 s; BMI=body mass index kg/m2; 6MW=6-minute 
walk test; QOL-B-RSS=Quality of Life-Bronchiectasis Respiratory Symptoms scores; 
SD=standard deviation; ABPA=allergic bronchopulmonary aspergillosis; COPD=chronic 
obstructive pulmonary disease; IBD=inflammatory bowel disease. *for cultured 
organisms numbers may not add up to 100% due to culturing of more than one 
organism per sputum sample. In addition, other organisms not included in the above 
groups were isolated including: Acromobacter xyloxidans (1), Aeromonas hydrophilia 
(2), Burkholderia cepacia (1), Pasteurella multocida (2), Haemophilus parainfluenzae 
(3), Pseudomonas fluorescens (1) and Stenotrophomonas maltophilia (3),  
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Table 2. Patient demographics of all population and from AIR-BX1 and AIR-BX2 studies 
included in the reanalyses.
Data are presented as n(%) unless otherwise indicated.
FEV1=forced expiratory volume in 1 s; 6MW=6-minute walk test; QOL-B-RSS=Quality of 
Life-
Bronchiectasis Respiratory Symptoms scores; SD=standard deviation. 
All
n=440
AIR-BX1
n=181
(40.9%)
AIR-BX2
n=259
(58.5%)
p value
Age, years
Mean (SD)
63.8 (12.8) 64.8 (11.5) 63.1 (13.7) 0.1
Female sex 306 (69%) 126 (69%) 180 (69%) 0.9
FEV1 % predicted
Mean (SD)
62.2 (20.3) 60.8 (19.8) 63.2 (20.7%) 0.2
6MWT distance
Mean (SD), m
422 (120) 421 (114) 423 (124) 0.8
QOL-B-RSS
Mean (SD)
55.9 (18.5) 54.6 (19.2) 56.7 (18.03) 0.2
Pseudomonas 
aeruginosa
357 (80%) 146 (80%) 211 (81%) 0.8
Treatment group 219 (49.4%) 89 (49.2%) 130 (50.2%) 0.8
Placebo group 221 (50.2%) 92 (50.8%) 129 (49.8%) 0.8
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Figure legends
Figure 1. Association between low (<105 cfu/g ) , moderate (105-6 cfu/g) and high 
(≥107cfu/g) bacterial load with Quality of Life-Bronchiectasis-Respiratory Symptoms 
(QoL-B-RSS) (Panel A), Bronchiectasis Severity Index (BSI) (Panel B), Forced expiratory 
volume in 1 second (Panel C), Neutrophil count in sputum (Panel D) and 
Myeloperoxidase (MPO) activity in sputum(Panel E). p value is from comparison of all 
groups (ANOVA tests for A-C, and Kruskall-Wallis test for C and D)
Figure 2. Mean bacterial load of patients with bronchiectasis at baseline, after 
receiving systemic antibiotic and after at least 3 month of follow-up (Panel A), and 
bacterial load at days 1,3,5,7 and 14 during clinically stability (Panel B). Patients are 
divided into high (green), moderate (orange) and low (blue) baseline bacterial load.
Figure 3. Changes in quantitative bacteriology during the study. The top panel shows 
the active treatment group (aztreonam) and the lower panel shows subjects treated 
with placebo. The yellow highlighted period indicates visits that took place during 
active treatment (visits 3, 4 and 6). Visit labels are as follows: visit 1= screening, visit 2= 
baseline, visit 3= 14 days on-treatment, vist 4= 28 days on treatment, visit 5= 28 days 
off-treatment, visit 6= 28-days on-treatment during the second cycle, visit 7= final visit, 
off treatment. 
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Figure 4. Changes in Quality of Life-Bronchiectasis-Respiratory Symptoms (QoL-B-RSS) 
from baseline to week 4 in bronchiectasis patients divided into high, moderate and low 
bacterial load. Data are presented as mean difference (boxes) and 95% confidence 
interval (plots) (Panel A). Percentage of patients with response in Quality of Life-
Bronchiectasis-Respiratory Symptoms Score (QoL-B-RSS) above the Minimum Clinically 
Important Difference according to bacterial load at week 4 (Panel B).
Figure 5. Percentage of patients with high bacterial load included in AIR-BX1 and AIR-
BX2 studies. p value is from t-student test (Panel A). Changes in Quality of Life-
Bronchiectasis-Respiratory Symptoms (QoL-B-RSS) from baseline to week 4 in patients 
with high bacterial load, divided into studies (AIR-BX1 and AIR-BX2), lung function 
(FEV1 50% or <50% of predicted value), sex (male of female), baseline quality of life 
(QoL-B-RSS 60 or <60 points) and the presence of P. aeruginosa. Data are presented 
as mean difference (boxes) and 95% confidence interval (plots).
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ONLINE SUPPLEMENTARY DATA
Airway bacterial load and inhaled antibiotic response in Bronchiectasis
Oriol Sibila 1,2, Elena Laserna 3, Amelia Shoemark 4, Holly R  Keir 4, Simon Finch 4, Ana Rodrigo-Troyano 1,2, 
Lidia Perea 2, Mike Lonergan 4, Pieter C Goeminne 5,6, James D Chalmers 4.
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METHODS:
Study 1 
We performed a cross-sectional study of consecutive adult patients with bronchiectasis 
attending a specialist bronchiectasis clinic at Ninewells Hospital, Dundee in the UK. The study was 
approved by the local research ethical committee and all participants gave written informed consent. 
Bronchiectasis was defined as presence of bronchial dilatation on high-resolution CT scanning with 
compatible clinical history of cough with sputum production and/or recurrent respiratory infections 10. 
The inclusion criteria were age >18 years, HRCT confirmed bronchiectasis affecting 1 or more lobes and 
the ability produce a spontaneous sputum sample for microbiology and biomarker measurement. 
Patients with cystic fibrosis, primary immunodeficiency (eg, common variable immunodeficiency), active 
malignant disease, active allergic bronchopulmonary aspergillosis, interstitial lung disease, active 
mycobacterial disease (including non-tuberculosis mycobacteria), HIV infection or long-term oral 
corticosteroid treatment were excluded. 
Sputum was processed for qualitative and quantitative bacteriology as previously described 15. 
Colony forming units (cfu) for each predominant pathogen were then identified by standard procedures 
and counted after 48 hours aerobic incubation on selective medium at 37ºC to determine the sputum 
bacterial load, expressed as log10cfu/gram (g) 18. A priori patients were divided into low bacterial load 
(<105 cfu/g), moderate bacterial load (105-106 cfu/g) and high bacterial load (≥107 cfu/g).
All patients were clinically stable as defined by the absence of an exacerbation that required 
antibiotic or steroid treatment within 4 weeks prior to inclusion at the time of clinical assessment. 
Demographic data was recorded as previously described 17. The Bronchiectasis Severity Index (BSI) and 
FACED scores were also calculated 19,20. 
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Quality of life was determined using Quality of Life-Bronchiectasis Respiratory Symptoms score 
(QoL-B-RSS). Scores are 0-100, with higher scores representing fewer symptoms 21. Spirometry was 
performed according to ERS/ATS recommendations for calculation of the forced expiratory volume in 1 
second percentage of predicted value. 
Neutrophil count in sputum was determined by cytospins. Sputum was ultracentrifuged at 50,000 
G for 90 minutes. Inflammatory markers in sputum (CXCL8, TNF-) were measured by ELISA (R+D systems, 
Abingdon, UK). Myeloperoxidase activity in sputum supernatants were measured by chromogenic assay 
as previously described 17. We hypothesized that bacterial load would be associated with quality of life, 
severity of disease, forced expiratory volume in 1 second, and airway neutrophil biomarkers. 
Study 2
Two prospective studies were performed to demonstrate the repeatability of a high bacterial 
load phenotype in bronchiectasis. These were single centre studies performed as a specialist 
bronchiectasis clinic at Ninewells Hospital, Dundee, UK. In the first study,26 patients with bronchiectasis 
(inclusion criteria as per study 1) were followed-up for one year, and sputum analyses were performed 
at baseline, after receiving systemic antibiotic treatment of at least 14 days due to an acute 
exacerbation 22 and after at least three months of recovery. Following the baseline visit patients were 
asked to contact the study team to report symptoms consistent with an exacerbation. If exacerbation 
was confirmed, using the British Thoracic Society definition of an exacerbation, the study team would 
prescribe antibiotics and proceed with taking an additional sputum sample for culture and biomarker 
measurement. Patients were asked to return to provide a further sputum sample at 14 days after 
antibiotic treatment and at 3 months post-treatment. The follow-up visit was deferred if the patient had 
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received further systematic antibiotics (excluding stable macrolide) in the 2 weeks prior the stable visit. 
Sample processing for microbiology and biomarker measurement was as described for study 1 above.
 In a second study of 10 stable patients with bronchiectasis (5 with idiopathic/post-infective and 5 with 
CF bronchiectasis) patients were followed-up for 14 days, and sputum analyses were performed at days 
1,3,5,7 and 14. Patients were free from antibiotic treatment for a minimum of 28 days prior to this 14 
day observation period.  Quantitative sputum analyses were performed at every visit. Sputum were 
processed as previously described 15. Demographic data, etiology, number of exacerbations in the 
previous year, lung function tests, and current inhaled or oral antibiotic treatments were recorded at 
inclusion. CF patients were included in the second study to validate that observations were consistent 
independent of aetiology. All patients were adults aged>18 years and were clinically stable at 
enrolment, defined by no antibiotic treatment for at least 4-weeks except for antibiotics taking 
prophylactically at stable dose. Patients were also asked to confirm the absence of 
exacerbation at the screening visit. Patients had to report daily sputum production and to be 
able to produce a sputum sample at the screening visit. Exclusion criteria for both groups were; 
inability to give informed consent; immunodeficiency, active mycobacterial infection; current 
smokers/ex-smokers of <1 year; active ABPA; pregnancy/breast feeding; long-term oxygen 
therapy and FEV1<25% predicted. In addition specific inclusion criteria for CF subjects were: A 
diagnosis of CF with two disease causing CF transmembrane conductance regulator mutations;. 
Inclusion criteria for BE subjects: idiopathic or post-infective BE confirmed on CT; Exclusion 
criteria were: active sarcoidosis; alpha-1-antitrypsin deficiency; poorly controlled asthma and 
active malignancy. Patients attended at 9am on each study day (1,3,5,7 and 14 post enrolment) 
and provided a sputum sample for biomarker measurement and microbiology. Spontaneous 
sputum, induced sputum following induction and 24 hour sputum collection from the previous 
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day were all collected as part of the study. We report only the spontaneous sputum results in 
this manuscript as they correspond to those obtained in study 1 and study 3. The primary 
objective of the study was to evaluate the day to day variability in sputum derived biomarkers 
including neutrophil biomarkers and airway bacterial load to facilitate power calculations for 
future studies. 
The hypothesis of our analysis of these two studies was that high bacterial load would be a 
stable characteristic of bronchiectasis and therefore patients with increased bacterial load would have 
consistent high bacterial load during stable state and would return to high bacterial load following 
antibiotic treatment.
Study 3
We conducted a secondary analysis of two randomized double-blind, placebo-controlled phase 3 
trials of Aztreonam for inhalation solution (AZLI) in bronchiectasis (AIR-BX1 and AIR-BX2) 5. These trials 
included patients with CT-chest scan confirmed bronchiectasis with a positive sputum or bronchoscopic 
culture for Gram-negative organism or treatment of exacerbation with Gram-negative coverage in the 
previous 5 years, positive sputum culture for target Gram-negative bacteria at screening, chronic 
sputum production and FEV1 ≥ 20% of predicted. Pre-defined target Gram-negative respiratory 
pathogens were species of Pseudomonas, as well as Achromobacter, Burkholderia, Citrobacter, 
Enterobacter, Escherichia, Klebsiella, Moraxella, Proteus, Serratia and Stenotrophomonas. Exclusion 
criteria were hospital admission in the previous 2 weeks, haemoptysis of more than 30 mL or antibiotic 
treatment in the previous 2 weeks, changes in other treatments in previous 4 weeks and current 
treatment for non-tuberculous mycobacteria infection. The study sponsor, Gilead, included in the 
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original consent form an optional consent for patients to allow future re-analysis of their data and 
sharing of their data with independent researchers. Only where the investigators and patients had 
signed this consent could the data be made available to us for analysis. 
Patients received two 4-week cycles of double-blind inhaled treatment with AZLI 75 mg or 
placebo given three times a day, separated by 4 weeks off-treatment. The study consisted for 7 visits, 
visit 1, screening, visit 2, baseline, visit 3 at 14 days after initiation of aztreonam or placebo, visit 4 at 28 
days after initiation of aztreonam or placebo, visit 5 after 28 days off aztreonam or placebo (end of off-
treatment period), visit 6 at the end of the second 28 day on-treatment cycle and visit 7 at the 
conclusion of the study when the patient was off-treatment. 
The primary endpoint was change in the QoL-B-RSS between baseline and week 4. Minimum 
Clinical Important Difference (MCID) was considered an increase of 8 points 21. Secondary outcomes 
were changes in the QoL-B-RSS at week 12, which was the end of the second cycle of double blind 
treatment.  Additional exploratory endpoints included changes in 6-minute walk distance at 4 weeks, 
change in the EQ5D questionnaire at 4 weeks, change in bacterial load at 4 weeks and the frequency of 
exacerbations during the study. 
Bacterial load in cfu /g of target Gram-negative pathogens was measured in sputum at baseline 
by a central laboratory.
Based on our own previous work 15,17, we divided patients a priori into 3 groups;  low bacterial 
load (<105 cfu/g), moderate bacterial load (105-106 cfu/g) and high bacterial load (≥107 cfu/g).
RESULTS
Table E1. Baseline characteristics of patients with bronchiectasis (n=26) included in the 
Exacerbation Study.
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Data is presented as median (IQR) or number (%).
MRC= Medical Research Council; FEV1=forced expiratory volume in 1 s; FVC=forced vital capacity; 
BMI=body mass index kg/m2; BSI= Bronchiectasis Severity Index.
Age (years) 68 (60-73)
Gender (% female) 16 (61.5%) 
MRC (dyspnea Score) 3 (2-4)
Smoking status (never) 22 (84.6%)
Aetiology
      Idiopathic
      Post-infective
      Others
12 (46.2%) 
6 (23.1%) 
8 (30.8%)
Reiff score 8 (5-10)
FEV1 (% predicted) 65.7 (42.1-85.6) 
FVC (% predicted) 75.6 (55.9-95.4) 
BMI (kg/m2) 23.6 (20.7-26.4)
Exacerbations previous year 3 (1-4)
BSI  total score 12 (7-16)
Page 41 of 44  AJRCCM Articles in Press. Published on 21-May-2019 as 10.1164/rccm.201809-1651OC 
 Copyright © 2019 by the American Thoracic Society 
Table E2.  Clinical characteristics of patients with bronchiectasis (n=10) included in the day to 
day variability study.
Data is presented as median (IQR) or number (%).
MRC= Medical Research Council; FEV1=forced expiratory volume in 1 s; BMI=body mass index kg/m2.
Age (years) 48.5 (22.7-68.5)
Gender (% female) 4 (40%) 
MRC (dyspnea Score) 1 (1-2)
Smoking status (never) 9 (90%)
Aetiology
      CF
      Post-infective
      Idiopathic
5 (50%)
3 (30%)
2 (20%)
Inhaled antibiotic 1 (10%)
FEV1 (% predicted) 70 (45.7-88.5) 
FEV1 (L) 2.4 (1.4-2.9)
BMI (kg/m2) 24 (20.2-27)
Exacerbations previous year 1 (0-3)
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Table E3. Patient demographics of all patients included in AIR-BX 1 and AIR-BX 2 studies and 
those who had consented to have their data reanalyzed.
AIR-BX1
n=266
(49.2%)
AIR-BX1
Reanalysis
n=181 
(40.9%)
AIR-BX2
n=274
(50.7%)
AIR-BX2
Reanalysis
n=259 
(58.5%)
Age, years
Mean (SD)
64.6 (12.5) 64.8 (11.5) 62.7 (13.3) 63.1 (13.7)
Female sex 181 (68%) 126 (69%) 190 (69%) 180 (69%)
FEV1 % predicted
Mean (SD)
62.4 (20.8) 60.8 (19.8) 63.6 (20.5) 63.2 (20.7%)
6MWT distance
Mean (SD), m
423 (118) 421 (114) 426 (124) 423 (124)
QOL-B-RSS
Mean (SD)
55.2 (19.3) 54.6 (19.2) 56.8 (18.0) 56.7 (18.03)
Pseudomonas aeruginosa 217 (82%) 146 (80%) 219 (80%) 211 (81%)
Treatment group 134 (50.3%) 89 (49.2%) 136 (49.6%) 130 (50.2%)
Placebo group 132 (49.6%) 92 (50.8%) 138 (50.3%) 129 (49.8%)
Data are presented as n(%) unless otherwise indicated.
FEV1=forced expiratory volume in 1 s; 6MW=6-minute walk test; QOL-B-RSS=Quality of Life-
Bronchiectasis Respiratory Symptoms scores; SD=standard deviation. 
p value >0.1 in all comparisons.
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Table E4. Patient demographics of patients included in the reanalysis according to bacterial load
Low
bacterial load
(n=147)
Moderate
bacterial load
(n=172)
High
Bacterial load
(n=102)
p value
Age, years
Mean (SD)
63.5 (12.7) 65.1 (12.3) 61.5 (14.0) 0.08
Female sex 95 (64%) 127 (73%) 71 (69%) 0.20
FEV1 % predicted
Mean (SD)
64.3 (21.1) 62.2 (20.3) 58.7 (18.8) 0.10
6MWT distance
Mean (SD), m
421 (126.4) 414 (110.9) 431 (128.3) 0.51
QOL-B-RSS
Mean (SD)
58.4 (18.0) 53.9 (18.6) 53.9 (17.9) 0.06
Pseudomonas 
aeruginosa
93 (63%) 156 (90%) 90 (88%) 0.00
Data are presented as n(%) unless otherwise indicated.
FEV1=forced expiratory volume in 1 s; 6MW=6-minute walk test; QOL-B-RSS=Quality of Life-
Bronchiectasis Respiratory Symptoms scores; SD=standard deviation. 
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